The effect of quercetin and berberine on pulmonary arterial hypertension

Investigation of the effect of quercetin and berberine on laboratory and functional indices of the heart and pulmonary vessels in patients with pulmonary arterial hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230220057462N1

Enrollment

140

Registered

2023-03-18

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension. Other secondary pulmonary hypertension

Interventions

Intervention 1: Control group: People included in this study group have RVSP above 35 mmHg and receive their classical treatments during the study period. Intervention 2: Intervention group 1: In this

Eligibility

Sex/Gender

All

Age

10 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with pulmonary artery hypertension

Exclusion criteria

Exclusion criteria: Liver disease kidney Diseases diabetes Specific diseases such as cancer and known vascular diseases

Design outcomes

Primary

Measure	Time frame
People with pulmonary artery peak systolic pressure >35 mm Hg. Timepoint: The first and last days of study. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Arterial oxygen saturation percentage. Timepoint: The first and last days of study. Method of measurement: Pulse oximeter.;High density lipoprotein. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Cholesterol. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Triglyceride. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Heart rate. Timepoint: The first and last days of study. Method of measurement: Pulse oximeter.;The diameter of the right ventricular cavity at the end of systole (RVESd). Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The size of the diameter of the right ventricular cavity at the end of diastole. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The percentage of the volume of blood that leaves the ventricle in each beat. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Shortening Fraction. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Pulmonary Velocity Acceleration time. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Pulmonary vessel resistance. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Tricuspid regurgitation velocity. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The level of superoxide dismutase. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;The level of glutathione peroxidase. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;The amount of malondialdehyde. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;Interleukin 6. Timepoint: The first and last days of study. Method of measurement: Elisa kit.;Tumor necrosis factor alpha. Timepoint: The first and last	—

Measure

Time frame

Arterial oxygen saturation percentage. Timepoint: The first and last days of study. Method of measurement: Pulse oximeter.;High density lipoprotein. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Cholesterol. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Triglyceride. Timepoint: The first and last days of study. Method of measurement: laboratory test.;Heart rate. Timepoint: The first and last days of study. Method of measurement: Pulse oximeter.;The diameter of the right ventricular cavity at the end of systole (RVESd). Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The size of the diameter of the right ventricular cavity at the end of diastole. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The percentage of the volume of blood that leaves the ventricle in each beat. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Shortening Fraction. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Pulmonary Velocity Acceleration time. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Pulmonary vessel resistance. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;Tricuspid regurgitation velocity. Timepoint: The first and last days of study. Method of measurement: Echocardiography.;The level of superoxide dismutase. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;The level of glutathione peroxidase. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;The amount of malondialdehyde. Timepoint: The first and last days of study. Method of measurement: The relevant kit.;Interleukin 6. Timepoint: The first and last days of study. Method of measurement: Elisa kit.;Tumor necrosis factor alpha. Timepoint: The first and last

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Najafipour

Kerman University of Medical Sciences

najafipourh@kmu.ac.ir+98 34 3222 4071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026